Autologous hematopoietic transplantation following COVID-19 infection

Marthilde Brzycki1, Robert Richard1,2, Nicholas Burwick1,2

  • 1Marrow Transplant Unit VA Puget Sound Health Care System Seattle WA USA.

Clinical Case Reports
|March 26, 2021
PubMed

Autologous hematopoietic cell transplantation following induction therapy is standard of care for most patients with newly diagnosed multiple myeloma (N Engl J Med 2017, 376; 1311). Though active COVID-19 infection is typically a contraindication to aggressive therapy, little is known about the safety of autologous transplantation after resolution of acute symptoms and undetectable pathogen by nasopharyngeal PCR.